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OBJECTIVES: Lower urinary tract symptoms (LUTS)
such as detrusor instability or urinary retention strongly
impacts quality of life, involving economical aspects and
social living. The aim of our investigation is to record
changes in hospitalizations, Urological, and general prac-
titioner visits before and after sacral nerve stimulation
therapy. Expenses for pads, catheters, and drugs are also
investigated. METHODS: From February 2000 to Sep-
tember 2002 we enrolled 62 patients in the economic
session of the Italian Sacral Nerve Modulation Registry
(mean age 50 years old, from 22 to 70). Economic data
was recorded in order to compare costs with clinical
results of sacral nerve modulation therapy in patients
with LUTS. In this group 41 were incontinent patients
(61% female) mean age 53; 21 patients (71% female)
mean age 46 had urinary retention. RESULTS: We per-
formed a quarterly analysis, comparing the baseline data
to the last follow up available (12 month). Visits to the
general practitioner decreased from 1.1 to 0.05 (p < 0.01),
visits to the urologist did not change signiﬁcantly from
baseline (1.5 to 1.2). Diagnostic tests decreased from 2 to
0.8 (p < 0.01). In the use of pads we observed a major
change from 2.1/day (3 months expenses per patient of
€120.96) to 0.5 (3 months expenses per patient of €28.8)
(p = 0.08); For urinary retention the use of catheters
decreased from 1.1 baseline (3 months expenses per
patient of €178.2) to 0.1 at 12 months (3 months
expenses per patient of €16.2) (p = 0.09). Drug con-
sumption decreased signiﬁcantly (p < 0.05) from €47.24
to €10.53. CONCLUSIONS: The reduction in daily con-
sumption of pads and catheters (which is the major cost-
driver of urinary disorders), but also the reduction of
costs due to general practitioner visits, diagnostic tests,
and drug consumption are signiﬁcantly changed.
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OBJECTIVES: An important complication of Benign
Prostate Hyperplasia, a bothersome condition of ageing
men, is Acute Urinary Retention (AUR). This condition
needs acute catheterisation and is a predisposing factor
for surgery. Removal of the catheter is only possible in a
minority of patients if no drugs are used. Alpha-blockers
may increase the success rate of removing the catheter and
decrease the need for future surgery. This study assessed
the costs of treating patients with AUR with alfuzosin,
watchful waiting or immediate prostatectomy in Belgium.
METHODS: According to a randomised controlled trial
(ALFAUR study) removing the catheter is successful in
47.9% of patients treated with watchful waiting and
61.9% of those treated with 3 days of alfuzosin (cost
€0.92 per day). Based on the treatment path and imme-
diate clinical outcome in the ALFAUR study, a medical
decision model to compare the costs and health effects of
the three possible strategies was built in Excel MS 2000,
whereby follow-up results were obtained from epidemio-
logical data. The cost of events was based on a patient
chart review (n = 63) in patients with a ﬁrst episode of
AUR and conducted from the health care payer’s per-
spective. The time horizon of the model was 6 months.
RESULTS: At 6 months, 32.3% of patients who initially
voided successfully were re-hospitalised to undergo a
prostatectomy. Six-month cost of patients treated with
alfuzosin, watchful waiting and immediate prostatectomy
were respectively €4175, €4758, and €6036. These results
were robust under a wide range of plausible assumptions.
CONCLUSIONS: Based on the current available clinical
data, a very small investment (3 units of alfuzosin) can
lead to important savings for the public health care payer
by treating all patients hospitalised with AUR with alfu-
zosin. Further research on utilities in these patients is
expected to strengthen this conclusion.
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AVF are recommended over catheters because they have
lower morbidity and costs. OBJECTIVES: The aim was
to evaluate the cost effectiveness according to patient’s
survival and the difference caused by the delay of an ade-
quate AVF implementation when starting periodical
haemodialysis PHD. Pts included: all pts but 19pts start-
ing PHD during 1996–2000 (n = 133). One deﬁned three
groups of pts according to the time in having deﬁnitive
AVF: Group 1 (G1) having an adequate functioning AVF
before initiating PHD and it lasting at least three months
(53%); G2 not having a AVF at the beginning of PHD,
but in the ﬁrst 3 months of the entrance in PHD (25%)
and G3 being using catheters for more than 3 months
(22%). Studied resources cost: the AVF execution and
patient’s medical care, the mean hospital admissions (HA)
and their mean length stay (LS), catheter cost and time of
personnel as direct and indirect costs. Beneﬁts were cal-
culated evaluating patient’s survival and drugs were not
included by the complexity and patient’s diversity.
RESULTS: G1 were younger than G2 and G3, had lower
infections and less attributable death, lower CI, less HA
and LS. Total AVF costs were estimated in €3071. It could
have been avoided about 11–15% because of catheter
infections and 12 attributed deaths. So mean beneﬁts
could have been €5400 respect to G2 and €6860 to G3.
